More Could Benefit from HIV Prevention Pill Truvada
Title: More Could Benefit from HIV Prevention Pill TruvadaCategory: Health NewsCreated: 11/24/2015 12:00:00 AMLast Editorial Review: 11/25/2015 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - November 25, 2015 Category: Infectious Diseases Source Type: news
More May Benefit from HIV Prevention Pill Truvada
Medication can prevent infection with the virus in people at high risk (Source: WebMD Health)
Source: WebMD Health - November 24, 2015 Category: Consumer Health News Source Type: news
More Could Benefit from HIV Prevention Pill Truvada
Medication can prevent infection with the virus in people at high risk
Source: HealthDay
Related MedlinePlus Pages: HIV/AIDS, HIV/AIDS Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 24, 2015 Category: Consumer Health News Source Type: news
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Now Included Among Recommended Regimens for Antiretroviral Treatment-Naive Individuals with HIV-1 Infection
The FDA recently approved the fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF) as a complete regimen for antiretroviral treatment (ART)-naive HIV-infected individuals 12 years or older. Based on efficacy and safety data from phase 3 randomized clinical trials, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents will include EVG/c/FTC/TAF among the Recommended Initial Regimens for ART-naive adults and adolescents with estimated creatinine clearance ≥ 30 mL/min (AI). For more information, see the Panel’s statement on EVG/c/FTC/TAF. (Source...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - November 20, 2015 Category: Infectious Diseases Source Type: news
New PrEP Campaign Aims To Fight S.-Shaming And Break Down Stigma
A new video-based campaign is working to address stigma within the lesbian, gay, bisexual and transgender (LGBT) community when it comes to PrEP (pre-exposure prophylaxis), a drug also known as Truvada that when taken daily has been proven effective in helping to preventing HIV transmission.
The "Time2PrEP" campaign from Public Health Solutions is a series of video shorts that talks to different individuals across the queer spectrum about their experiences with PrEP and why they utilize the groundbreaking medication. Kenny Neal Shults of ConnectedHealthSolutions.com told The Huffington Post:
"When we sat dow...
Source: Healthy Living - The Huffington Post - November 15, 2015 Category: Consumer Health News Source Type: news
Uganda: Truvada Effective for HIV Prevention
[Observer] Preliminary results from a demonstration study being conducted by the Infectious Diseases Institute (IDI) show that Truvada offers discordant couples up to 70 per cent protection when used for preexposure prophylaxis (PrEP). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - November 11, 2015 Category: Infectious Diseases Source Type: news
FDA Clears New Combo Pill Genvoya for HIV-1 InfectionFDA Clears New Combo Pill Genvoya for HIV-1 Infection
Genvoya combines elvitegravir, cobicistat, emtricitabine, and a new form of tenofovir, which appears to have a better safety profile than tenofovir disoproxil fumarate. FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - November 6, 2015 Category: Pediatrics Tags: HIV/AIDS News Alert Source Type: news
FDA Approves Genvoya (a Fixed-Dose Combination Tablet) to Treat HIV Infection
“The U.S. Food and Drug Administration today [November 5, 2015] approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. …
“Genvoya is approved for use in HIV-infected adults and children ages 12 years and older weighing at least 35 kilograms (77 pounds) who have never taken HIV therapy (treatment-naïve) and HIV-infected adults whose HIV-1 virus is currently suppressed. While Genvoya is not recommended fo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - November 6, 2015 Category: Infectious Diseases Source Type: news
FDA approves new treatment for HIV
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 5, 2015 Category: American Health Source Type: news
Where Do Gay Guys Go For Sex?
Each week HuffPost Gay Voices, in a partnership with blogger Scout, LGBT HealthLink and researcher Susana Fajardo, brings you a round up of some of the biggest LGBT wellness stories from the past seven days. For more LGBT Wellness visit our page dedicated to the topic here. Where Do Guys Go for Sex? A new study looked at where HIV-positive Baltimore men went to find sex partners. 31% went to bars/clubs and 38% went to the Internet, but there was a shift over time away from bars/club towards the Internet. Is everyone just swiping right now? HRC: Bisexuals Have Worse Health The HRC released a new report highlighting th...
Source: Healthy Living - The Huffington Post - September 21, 2015 Category: Consumer Health News Source Type: news
Boston Man Sues Mutual Of Omaha Over Use Of HIV-Blocking Drug
BOSTON (AP) — As a gay man, the Boston attorney thought he was doing the responsible thing when he asked his doctor to prescribe Truvada, a drug hailed as a way to halt the spread of AIDS. But when he tried to get long-term care insurance, Mutual of Omaha turned him down, saying it does not offer coverage to anyone who takes the drug.
Now, the man is planning to sue the insurer, alleging he was discriminated against because he is gay. He filed a complaint Wednesday with the Massachusetts Commission Against Discrimination, the first step in a lawsuit.
The man, who is identified only as John Doe in the complaint, said he w...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 17, 2015 Category: Consumer Health News Authors: miketoole Tags: Health Local News HIV Insurance Source Type: news
Nigeria: Study to Decide Best HIV Treatment Strategy
[Daily Trust] A study by the National Agency for Control of AIDS (NACA) is to help decide whether health workers choose to administer the antiretroviral drug, Truvada-as a prevention or treatment for HIV/AIDS. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - September 10, 2015 Category: Infectious Diseases Source Type: news
PrEP HIV drug 'PREVENTS the virus developing in 100% of healthy gay men'
Scientists at the Kaiser Permanente San Francisco Medical Center gave Truvada, a pre-exposure prophylaxis (PrEP) to hundreds of gay men, and found that none of developed HIV. (Source: the Mail online | Health)
Source: the Mail online | Health - September 8, 2015 Category: Consumer Health News Source Type: news
Truvada Protected 100 Percent Of Study Participants From HIV
A study of 657 people taking PrEP, the daily pill that can prevent HIV, has found that not a single person contracted the potentially deadly virus over two and a half years of observation. The research showed that despite rising rates of STIs in the group, as well as a decline in condom use, the pill was able to protect everyone involved from HIV. The study was conducted by doctors from Kaiser Permanente, a managed care company based in Oakland, California. "What our study shows very reassuringly is that PrEP works in a real world setting," said lead researcher Dr. Jonathan Volk of Kaiser Per...
Source: Healthy Living - The Huffington Post - September 4, 2015 Category: Consumer Health News Source Type: news
Insurer Says Clients on Daily Pill Have Stayed H.I.V.-Free
The finding contradicts critics’ predictions that pre-exposure prophylaxis, or PrEP, would lead to less condom use and more H.I.V. infections. (Source: NYT Health)
Source: NYT Health - September 2, 2015 Category: Consumer Health News Authors: DONALD G. McNEIL Jr. Tags: Clinical Infectious Diseases (Journal) Volk, Jonathan E. Sexually Transmitted Diseases Acquired Immune Deficiency Syndrome Kaiser Permanente San Francisco (Calif) Condoms Homosexuality and Bisexuality Truvada (Drug) Source Type: news
